Edition:
United States

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

19.20USD
17 Aug 2018
Change (% chg)

$-0.38 (-1.94%)
Prev Close
$19.58
Open
$19.52
Day's High
$19.58
Day's Low
$19.12
Volume
941,683
Avg. Vol
1,267,567
52-wk High
$32.49
52-wk Low
$18.50

Chart for

About

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's... (more)

Overall

Beta: 2.03
Market Cap(Mil.): $5,722.28
Shares Outstanding(Mil.): 298.04
Dividend: --
Yield (%): --

Financials

  EXEL.OQ Industry Sector
P/E (TTM): 18.60 99.36 30.45
EPS (TTM): 1.03 -- --
ROI: 52.55 2.89 12.63
ROE: 70.00 1.65 14.82

BRIEF-Exelixis Appoints Andrew Peters To Newly Created Position Of Vice President, Strategy

* EXELIXIS APPOINTS ANDREW R. PETERS TO NEWLY CREATED POSITION OF VICE PRESIDENT, STRATEGY Source text for Eikon: Further company coverage:

May 22 2018

BRIEF-Exelixis Says Phase 3 Imblaze370 Study Did Not Meet Its Primary Endpoint Of Improving Overall Survival Vs Regorafenib

* EXELIXIS PROVIDES UPDATE ON IMBLAZE370 PHASE 3 PIVOTAL TRIAL OF ATEZOLIZUMAB AND COBIMETINIB IN PATIENTS WITH HEAVILY PRETREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER

May 10 2018

BRIEF-Exelixis Inc Q1 Earnings Per Share $0.37

* EXELIXIS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 02 2018

BRIEF-Exelixis And Invenra Enter Into Collaboration To Develop Novel Biologics To Treat Cancer

* EXELIXIS AND INVENRA ENTER INTO COLLABORATION TO DISCOVER AND DEVELOP NOVEL BIOLOGICS TO TREAT CANCER

May 02 2018

BRIEF-Exelixis Says CEO Michael Morrissey's FY 2017 Total Compensation Was $9.4 Mln VS $6.3 Mln

* EXELIXIS INC SAYS CEO MICHAEL MORRISSEY'S FY 2017 TOTAL COMPENSATION WAS $9.4 MLN VS $6.3 MLN IN 2016 - SEC FILING Source text: (https://bit.ly/2Hi8UXj) Further company coverage:

Apr 12 2018

BRIEF-Exelixis Says Board Increased Size Of Board To 12 Members

* EXELIXIS SAYS BOARD INCREASED SIZE OF BOARD TO 12 MEMBERS - SEC FILING Source text: (https://bit.ly/2uWDtwR) Further company coverage:

Apr 09 2018

BRIEF-Exelixis Says Ipsen received validation of the application for variation to the Cabometyx

* EXELIXIS’ PARTNER IPSEN ANNOUNCES EMA VALIDATION OF THE APPLICATION FOR A NEW INDICATION FOR CABOMETYX® (CABOZANTINIB) FOR PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

Mar 28 2018

BRIEF-Exelixis' Partner Ipsen Announces Positive CHMP Opinion For Cabometyx

* EXELIXIS' PARTNER IPSEN ANNOUNCES POSITIVE CHMP OPINION FOR CABOMETYX FOR PREVIOUSLY UNTREATED INTERMEDIATE- OR POOR-RISK ADVANCED RENAL CELL CARCINOMA​

Mar 23 2018

BRIEF-Exelixis Submits U.S. Supplemental NDA For Cabometyx

* EXELIXIS SUBMITS U.S. SUPPLEMENTAL NEW DRUG APPLICATION FOR CABOMETYX (CABOZANTINIB) FOR PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA Source text for Eikon: Further company coverage:

Mar 15 2018

BRIEF-Daiichi Sankyo's Regulatory Submission Triggers $20 Mln Milestone Payment To Exelixis​

* CO ‍ANNOUNCES COLLABORATOR DAIICHI SANKYO'S SUBMISSION OF REGULATORY FILING FOR ESAXERENONE (CS-3150) IN JAPAN​

Feb 26 2018

Competitors

Earnings vs. Estimates